Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Management of patients with advanced prostate cancer in Japan: 'real-world' consideration of the results from the Advanced Prostate Cancer Consensus Conference.
Fujita K, Suzuki H, Hinata N, Miura Y, Edamura K, Tabata KI, Arai G, Matsubara N, Yasumizu Y, Kosaka T, Oya M, Sugimoto M. Fujita K, et al. Among authors: tabata ki. Transl Androl Urol. 2022 Dec;11(12):1771-1785. doi: 10.21037/tau-22-396. Transl Androl Urol. 2022. PMID: 36632151 Free PMC article. Review.
Predictive Value of the Prostate-specific Antigen Doubling Time for the Effectiveness of Metastasis-directed Radiotherapy in Patients With Oligometastases After Radical Treatment for Non-metastatic Prostate Cancer.
Koguchi D, Tabata KI, Hirano S, Shimura S, Satoh T, Ikeda M, Matsumoto K, Niibe Y, Iwamura M. Koguchi D, et al. Among authors: tabata ki. Cancer Diagn Progn. 2024 Sep 1;4(5):638-645. doi: 10.21873/cdp.10375. eCollection 2024 Sep-Oct. Cancer Diagn Progn. 2024. PMID: 39238621 Free PMC article.
Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer.
Tanegashima T, Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Kitamura H, Kamoto T, Eto M; Japanese Urological Oncology Group. Tanegashima T, et al. Among authors: tabata ki. Int J Clin Oncol. 2024 Dec 17. doi: 10.1007/s10147-024-02681-2. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39688742
Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide.
Kawahara T, Saigusa Y, Yoneyama S, Kato M, Kojima I, Yamada H, Kamihira O, Tabata K, Tsumura H, Iwamura M, Makiyama K, Uemura H, Miyoshi Y. Kawahara T, et al. BMC Cancer. 2023 Mar 7;23(1):214. doi: 10.1186/s12885-023-10700-0. BMC Cancer. 2023. PMID: 36882764 Free PMC article.
Cancer-specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy.
Narita S, Terada N, Nomura K, Sakamoto S, Hatakeyama S, Kato T, Matsui Y, Inokuchi J, Yokomizo A, Tabata KI, Shiota M, Kimura T, Kojima T, Inoue T, Mizowaki T, Sugimoto M, Kitamura H, Kamoto T, Nishiyama H, Habuchi T; Japanese Urological Oncology Group. Narita S, et al. Among authors: tabata ki. Int J Urol. 2022 Oct;29(10):1147-1154. doi: 10.1111/iju.14938. Epub 2022 May 25. Int J Urol. 2022. PMID: 35613936
Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer.
Tsumura H, Tanaka N, Oguchi T, Owari T, Nakai Y, Asakawa I, Iijima K, Kato H, Hashida I, Tabata KI, Satoh T, Ishiyama H. Tsumura H, et al. Among authors: tabata ki. Radiat Oncol. 2022 Apr 11;17(1):71. doi: 10.1186/s13014-022-02046-x. Radiat Oncol. 2022. PMID: 35410307 Free PMC article.
65 results